{"ticker": {"uuid": "df00a65e-5367-422f-97a6-b0f2eecc593e", "symbol": "LXRX", "name": "Lexicon Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What Lexicon Pharmaceuticals (LXRX)'s Broad Russell Index Inclusion Means For Shareholders", "summary": "Lexicon Pharmaceuticals (LXRX) was recently included in several Russell indexes, including the Russell 2000 and 3000, which could boost its trading liquidity and attract new investors. However, this inclusion doesn't change the company's fundamental investment narrative, which st", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals/news/what-lexicon-pharmaceuticals-lxrxs-broad-russell-index-inclu", "source_name": "Simply Wall Street", "published_at": "2026-07-10T08:40:11", "published_display": "10 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) Short Interest & Short Float | Updated Jul 2026 $LXRX", "summary": "Lexicon Pharmaceuticals (LXRX) experienced a 21.08% increase in short interest as of June 30, 2026, reaching 30.78 million shares, representing 8.06% of the public float. The short interest ratio or \"days to cover\" stands at 4.4 days, indicating the time it would take to cover al", "url": "https://www.marketbeat.com/stocks/NASDAQ/LXRX/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-10T07:11:09", "published_display": "10 Jul 2026 07:11", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals highlights diabetes drug focus. Strategy matters more than near-term headlin", "summary": "Lexicon Pharmaceuticals (LXRX) is maintaining its focus on diabetes and metabolic disease therapies, emphasizing its pipeline strategy within the competitive US biopharma market. The company develops targeted therapies for defined patient populations, concentrating on cardiometab", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/lexicon-pharmaceuticals-highlights-diabetes-drug-focus-strategy-matters/69717350", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T21:51:00", "published_display": "07 Jul 2026 21:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Lexicon Pharmaceuticals Inc (LXRX)", "summary": "This article examines the historical performance of investing $1,000 in Lexicon Pharmaceuticals Inc (LXRX) over one, five, and ten years, comparing its returns to the S&P 500. It also provides an in-depth profile of Lexicon Pharmaceuticals, detailing its biopharmaceutical product", "url": "https://www.stocktitan.net/tools/stock-return-calculator/LXRX", "source_name": "Stock Titan", "published_at": "2026-07-04T04:09:42", "published_display": "04 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion", "summary": "Lexicon Pharmaceuticals (LXRX) has seen more than a 15% gain over the past month, largely due to its inclusion in the Russell 3000 index and strong Q1 2026 earnings, which surpassed expectations significantly. The company reported $21.1 million in revenue, a 1,523% year-over-year", "url": "https://www.insidermonkey.com/blog/lexicon-pharmaceuticals-lxrx-gains-on-russell-3000-inclusion-1794180/", "source_name": "Insider Monkey", "published_at": "2026-07-03T13:39:35", "published_display": "03 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Lexicon Pharma\u2019s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX)", "summary": "Lexicon Pharmaceuticals, Inc. was added to various Russell indexes on June 27, 2026, increasing its visibility to institutional investors. While this expanded index inclusion is significant for potential trading volume and ownership, the company's core investment narrative still ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals/news/how-lexicon-pharmas-expanded-russell-index-footprint-shapes", "source_name": "Simply Wall Street", "published_at": "2026-07-02T04:09:42", "published_display": "02 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) Joins Russell Indexes, Is The Stock Still A Bargain?", "summary": "Lexicon Pharmaceuticals (LXRX) has been added to multiple Russell indexes, which is expected to increase its visibility among investors after a period of strong share price growth. Despite a \"most popular narrative\" suggesting the stock is 30% undervalued at $3.77 due to its prom", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals/news/lexicon-pharmaceuticals-lxrx-joins-russell-indexes-is-the-st", "source_name": "Simply Wall Street", "published_at": "2026-06-30T05:10:26", "published_display": "30 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2500 Growth Benchmark", "summary": "Lexicon Pharmaceuticals, Inc. (NasdaqCM:LXRX) has been added to the Russell 2500 Growth Benchmark. The biopharmaceutical company is actively involved in the research and development of drug candidates and the commercialization of INPEFA (sotagliflozin) for heart failure and type ", "url": "https://www.marketscreener.com/news/lexicon-pharmaceuticals-inc-nasdaqcm-lxrx-added-to-russell-2500-growth-benchmark-ce7f5fdfdb8bf32c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:26:00", "published_display": "29 Jun 2026 16:26", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Growth Benchmark", "summary": "Lexicon Pharmaceuticals, Inc. (NasdaqCM:LXRX) has been added to the Russell 2000 Growth Benchmark. The biopharmaceutical company focuses on researching and developing drug candidates and commercializing INPEFA (sotagliflozin), which reduces cardiovascular risks. Lexicon is also d", "url": "https://www.marketscreener.com/news/lexicon-pharmaceuticals-inc-nasdaqcm-lxrx-added-to-russell-2000-growth-benchmark-ce7f5fdedc8ff326", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:12:54", "published_display": "29 Jun 2026 15:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000E Growth Benchmark", "summary": "Lexicon Pharmaceuticals, Inc. (NasdaqCM:LXRX) has been added to the Russell 3000E Growth Benchmark. The biopharmaceutical company focuses on researching, developing, and commercializing drug candidates, including INPEFA (sotagliflozin) for cardiovascular and kidney conditions, pi", "url": "https://www.marketscreener.com/news/lexicon-pharmaceuticals-inc-nasdaqcm-lxrx-added-to-russell-3000e-growth-benchmark-ce7f5fdedb81f625", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T03:44:06", "published_display": "29 Jun 2026 03:44", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LXRX Surges As Traders Pounce On Strong Breakout", "summary": "Lexicon Pharmaceuticals Inc. (LXRX) stock has surged by 11.76% due to bullish sentiment driven by promising drug development progress. The stock has broken out from low $2s to above $2.55, indicating strong buying pressure despite the company's significant operating losses. Analy", "url": "https://stockstotrade.com/news/lexiconpharmaceuticalsinc-lxrx-news-2026_06_28/", "source_name": "StocksToTrade", "published_at": "2026-06-28T15:37:00", "published_display": "28 Jun 2026 15:37", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LXRX Stock Climbs As Bullish Momentum Attracts Short-Term Traders", "summary": "Lexicon Pharmaceuticals Inc. (LXRX) stock has climbed by 11.76% due to positive drug development news and bullish investor sentiment. Despite rapid revenue growth, the company faces deep losses, but strong liquidity provides a runway for operations. Technical analysis indicates a", "url": "https://stockstotrade.com/news/lexiconpharmaceuticalsinc-lxrx-news-2026_06_27/", "source_name": "StocksToTrade", "published_at": "2026-06-27T15:10:31", "published_display": "27 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LXRX Climbs As Bulls Press Multi-Day Breakout", "summary": "Lexicon Pharmaceuticals Inc. (LXRX) is experiencing a multi-day breakout driven by positive drug development news, with its stock climbing significantly. Despite strong revenue growth, the company faces deep losses, but its strong balance sheet and high liquidity provide a runway", "url": "https://www.timothysykes.com/news/lexiconpharmaceuticalsinc-lxrx-news-2026_06_27/", "source_name": "Timothy Sykes", "published_at": "2026-06-27T14:10:31", "published_display": "27 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals stock hits 52-week high at $2.53 By Investing.com", "summary": "Lexicon Pharmaceuticals (LXRX) stock reached a 52-week high of $2.53, showing significant momentum with increases of approximately 14% over the past week, 86% over six months, and 99% year-to-date, reflecting a 206.37% increase over the last year. Despite this surge and a strong ", "url": "https://ng.investing.com/news/stock-market-news/lexicon-pharmaceuticals-stock-hits-52week-high-at-253-93CH-2576373", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T14:10:26", "published_display": "27 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals stock hits 52-week high at $2.53", "summary": "Lexicon Pharmaceuticals (LXRX) stock reached a 52-week high of $2.53, showing strong momentum with significant gains over the past week, six months, and year-to-date. This performance, coupled with revenues surging to $21.1 million in Q1 2026, reflects investor confidence, though", "url": "https://www.investing.com/news/company-news/lexicon-pharmaceuticals-stock-hits-52week-high-at-253-93CH-4763333", "source_name": "Investing.com", "published_at": "2026-06-27T13:39:27", "published_display": "27 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:LXRX)", "summary": "This article provides an overview of Lexicon Pharmaceuticals, Inc. (LXRX) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financials, such as recent revenue and net income, market capitalization, and upcoming earnin", "url": "https://www.tradingview.com/symbols/NASDAQ-LXRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T00:38:50", "published_display": "26 Jun 2026 00:38", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why You Should Add LXRX Stock to Your Portfolio Now", "summary": "Lexicon Pharmaceuticals (LXRX) is highlighted as an investment opportunity due to its advancing cardiometabolic franchise, primarily driven by its drug sotagliflozin (Inpefa). The company is pursuing label expansion for sotagliflozin into hypertrophic cardiomyopathy and type 1 di", "url": "https://www.tradingview.com/news/zacks:046657109094b:0-here-s-why-you-should-add-lxrx-stock-to-your-portfolio-now/", "source_name": "TradingView", "published_at": "2026-06-22T14:40:38", "published_display": "22 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Stock - Sunday background on strategy and trials", "summary": "This article provides background on Lexicon Pharmaceuticals (LXRX), a biotech company focusing on cardiovascular and metabolic diseases. It highlights the company's approved heart failure drug Inpefa, its clinical development strategy, and financial considerations. While there wa", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/lexicon-pharmaceuticals-stock-sunday-background-on-strategy-and-trials/69598354", "source_name": "AD HOC NEWS", "published_at": "2026-06-21T18:10:52", "published_display": "21 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Inc (LXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Lexicon Pharmaceuticals Inc (LXRX) has an earnings forecast score of 7.60, ranking 281st in the Biotechnology & Medical Research industry. Analysts project an average price target of $1.90 with a \"Buy\" rating based on 5 analysts. The company's recent EPS was -$0.04, with the next", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lxrx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T06:41:23", "published_display": "18 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Inc (LXRX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Lexicon Pharmaceuticals Inc (LXRX) currently holds a financial score of 8.90, ranking 23rd in the Biotechnology & Medical Research industry, indicating stable financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 157", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lxrx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T05:41:23", "published_display": "18 Jun 2026 05:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Inc (LXRX) Institutional Confidence", "summary": "Lexicon Pharmaceuticals Inc (LXRX) has an institutional shareholding score of 5.00, placing it 133rd out of 388 in its industry. The institutional shareholding proportion is 67.79%, a slight decrease from the previous quarter. Steven Cohen is the largest institutional shareholder", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lxrx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T02:41:23", "published_display": "18 Jun 2026 02:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Peripheral Neuropathic Pain Market Positioned for Significant Commercial Growth by 2034 \u2013 DelveInsight | Gr\u00fcnenthal and Averitas Pharma, Scilex Pharma, Apurano Pharma, Lexicon Pharma, Helixmith", "summary": "The Peripheral Neuropathic Pain market is projected for significant growth by 2034, driven by increasing disease prevalence, awareness, and the launch of multiple pipeline products. In 2023, the global market was valued at approximately USD 12,000 million, with the US showing the", "url": "https://www.barchart.com/story/news/2482391/peripheral-neuropathic-pain-market-positioned-for-significant-commercial-growth-by-2034-delveinsight-grnenthal-and-averitas-pharma-scilex-pharma-apurano-pharma-lexicon-pharma-helixmith", "source_name": "Barchart.com", "published_at": "2026-06-16T22:09:10", "published_display": "16 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals vs Pfizer: Comparing a Small Biotech with a Global Drugmaker - News and Statistics", "summary": "This article compares Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE), highlighting the contrast between a small, growing biotech firm and a large, established pharmaceutical giant. It delves into their recent financial performances, noting Lexicon's significant revenue growth bu", "url": "https://www.indexbox.io/blog/lexicon-pharmaceuticals-vs-pfizer-biotech-growth-vs-pharma-scale-in-2026/", "source_name": "IndexBox", "published_at": "2026-06-11T15:10:18", "published_display": "11 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/ede98e74-9fd6-3733-b068-fb42fba270a9/lexicon-pharmaceuticals-vs..html", "source_name": "Motley Fool", "published_at": "2026-06-11T14:05:55+00:00", "published_display": "11 Jun 2026 14:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQRlBLNVlPOWk3bEstSU5CMFRMUGtiYU9NUkluMThVZHNJUUF4dnRIZnNZckczenpVTnhMdVFXbFJURE0zVExpZm5zTnl4WEpyWUh1WVREVUxDekdRZ2UtenFiY2tSSC1DUGozRTVqVnU5Ry1lS3pabHBJbFMxdWhON09RYUdsNHJHTDdpa3VqTE01eDNkS1R3MkRLVUlKZko0RXZSdA?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) director exercises 89,312 RSUs into shares", "summary": "Lexicon Pharmaceuticals director Ivan Cheung converted 89,312 restricted stock units (RSUs) into common shares on June 3, 2026, at a price of $0.00 per share. Following this non-cash equity award event, Cheung directly holds 89,312 common shares, with no remaining restricted stoc", "url": "https://www.stocktitan.net/sec-filings/LXRX/form-4-lexicon-pharmaceuticals-inc-insider-trading-activity-c08ebc12c05f.html", "source_name": "Stock Titan", "published_at": "2026-06-05T17:39:57", "published_display": "05 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into 213,771-share stake", "summary": "Lexicon Pharmaceuticals director Sam L. Barker converted 89,312 restricted stock units (RSUs) into common shares on June 3, 2026, receiving 89,312 shares at $0.00 per share. This transaction was an equity compensation event, not an open-market trade. Following the conversion, Bar", "url": "https://www.stocktitan.net/sec-filings/LXRX/form-4-lexicon-pharmaceuticals-inc-insider-trading-activity-87d03f6ffef5.html", "source_name": "Stock Titan", "published_at": "2026-06-05T04:08:54", "published_display": "05 Jun 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] LEXICON PHARMACEUTICALS, INC. Insider Trading Activity", "summary": "LEXICON PHARMACEUTICALS, INC. director Christopher J. Sobecki exercised 89,312 restricted stock units, converting them into an equivalent number of common shares. Following this transaction, his direct holdings in the company amount to 293,177 shares of common stock. The transact", "url": "https://www.stocktitan.net/sec-filings/LXRX/form-4-lexicon-pharmaceuticals-inc-insider-trading-activity-486e19991df5.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:39:14", "published_display": "04 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQal9jcWdHa0ZtcVJlcmNuSnRkSThHck44UGJuU0hkQU1jOEZpejJXeExiOEk1dGhXUlJNVE12R2hpbDlRUVgtYkx6cDBGVzdmRDJPenJEeE05VlkyUVZLSEV2RUM1c284Y0NnUldVdGY2Sjg3WF96eEZXY1lOSUUtS3N2M0JwVktva2RQM2tSNm1BR0x6NHkyUGpPZm1UaXg3aTlYVDdkaE9NbkJhdWNLNFEyaDg?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into common stock holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOMW82d1p5eFlCSlZuTWdDTi03dU0xTGJIMTFaeGpyR0ZwRktOQ0tnTHJQSnl5RzlVaUVrSlVoWU5nQldCS2RFbDZIRnlQRkNJdnZIRldDMWNPVmQtRjhUYlVFb0xlTlZ2V3dOR1Q0V2tSTkZMRUtSNDhidUpDWmVKaG1GRTRTby12NkZxTFhtbWlweXdwZElaMDhxcmpYN1UweHdDS29RNUdLclpGNHQ1MEQxMS1rRXNDb1IwdG5n?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexicon-present-data-american-diabetes-120000318.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T12:00:00+00:00", "published_display": "03 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Type 1 diabetes drug data from Lexicon at ADA 2026 meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSi1aeXJUS1RrTVp2Zi1mRGFfZUpLWnJYeU5STmpKdEtVMklnSWtXUVBlT1pIOXk1X0pqSEhDemxGdkh1akJwLVBFb1hfT2JnMHBIci14eTI2NlYwaEwzVWVlZkpHem1NaE41eDRLdW5GeDlxdTN5R3FsLU80WktwdGkxSjAyUHpMUkQ1TVFHNGNraW9GNEVkU24zdkNERk1LRDAxc2hWOHNVVTlidGhGX2FTZmltSWlUcW9N?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon (LXRX) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/4e91607c-2f3b-3678-ad4a-0f55b2b9dee4/lexicon-%28lxrx%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-06-01T20:40:21+00:00", "published_display": "01 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexicon-pharmaceuticals-present-2026-jefferies-123000623.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:30:00+00:00", "published_display": "28 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharma schedules Jefferies healthcare fireside chat for June 4", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPdFdzSE1pWURwQTJWNVNOSGpJYl9PQVRSLTROeFNhdkQwSTNDV2d2c2cwcXlubnBZSnJvajNnb3VzZjVYc3hQeVY1czg3Y0Roc0RpTGlqd2JkeWpaX3U1aDloOGgySEVqS3pFZjI1N2NOM0xYNm0wc3RYTXZWRWlCdFpEU3NBYmx4cEtHT1J1cG5NRVVKRjM0UDhyazBHMDBYX2NlbC1DaXpzVi1ZQ3NjR0puQXA0Y1RwVFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPX2FTbGpINHRlbE1SUlZDQ1BPa001QUhkT0FmMjNJbzU1aXdveHhrLTZPRHVibHVyTkdQenRTREt2dXFyRVZIVEROX2dfUUE3STJUdXNXWWNWR0VGUERsZno2T3pEMklYOFhmdnR0blZxbjFVa19LZk0xRUJCZ0F3bFdOSzNIMmR3ZHMyMzR0dnVmV01TYTM3NVhFVjNwQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexicon-pharmaceuticals-present-4th-annual-123000389.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T12:30:00+00:00", "published_display": "12 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply \u2013 What's Changed", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOajkxdGU5RVBiMzcwUWF4bGR2dzB6dFd3MnBwanE3WmxXeGRpM0cyZHhoM2lsUHplNTV1UmgwMmZmRFo4Ty1WSVlrRUZoSnFDbFlpZGlMSmtqTGY2dXBWbXdDU01kS0hobGk0YWJqbFVIT3hJTjJHeDlBYWY4TVk3clZyV0lWdw?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fireside chat at Nasdaq HQ: Lexicon joins H.C. Wainwright investor event May 19", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPblA4QUtzaWljZzlTSUU1Zk03b3JDVGlnVFBZeEVzS01zaDBPZDRORjRhbk0xUXAwSnNfQlRhbVJLNXN1VzFBRnFsYzA3eWFDRG5WN0gwU1BTaU9BTGd4Z0NQQjFXY3NtZTRRam56MEdPSC1FUXNTNGxuWkJmb2JENFcxZnVqZWVLeUdOUllZZW1VYWNHUXJ1QVlxeVdXbUttdlJpRkF2U2xMY05RRnZtWDVySlpjVzJjVjVaZ093SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQX2RiMV84RU14NklhcjdIMTVJSzNmQmNDcWRpeF95V0QybUtacUZEVkNKQllNZF9ab1p0aFJnYktXcG1TckJnaXFYY3oyQnhZRGpfcy1DdFY0TGZzV0JnZFR6bVppVXcwMzNneDFNalROdi14U2NRa3JPbTJ4eDJGbEo5VHlVWGo4bEFNZ0w0NTdqQVB1TzlMOUFGQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNX0VNbGthY2RJNnB5aTNEQ293UlN3SEthd01wMWhhdC1wRWFqaF9JNGJVUnZuTWZ1eTJ3V3l1LTFubGZ2NEtjWEg3MDBiRXJYRWhpLTVONTR0T2xReUFJY2dVNHRCTk4yaXNsOGRUQVhJeUdhQlZpY040SnRacVFldWswM19NVzY1NTZRRmhNNzJhTGJlNGIyS19YMmdCZ1RUWkVWazE0ZlpBQ3JES1E?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) Quarterly Revenue Drop Reinforces Concerns Over Persistent Losses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon targets diabetes filing, heart trial, obesity study milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOMW5yMHlmYUJXRk9adF9vc3pqT3pFY0Rkckp1ZUVlNzcxWnBDbUhBQWg1LTlmdGlRUXNYUHUxa3ZSWW1saFMtaXZfSFpGTUw0SVd2UF9XR0NRWEoxN2NuNEdkckhBb3AwU2JLTDB3bEJqSk5oYWdydlJXc1dxMmRKMmxDOXQ5WjM0TUJTZzBqQXozT25Kc2V4VTVWMWRUNGNKY1VrTHVDMXB1b2ZiV05kZDY1T3RCdmpObzFvS3BzR3Y?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNN2ExOHBkajhTVFNvYU1RTDZXNVlzSWNZTFQ2REVYRVdzVDVSYkIweWhtSGRBVlB5bFM1d1dfa0tjNGRkRm8zdTlUTnFNM3BVdnV0VTcwVlE4Q1pLcTluUmYtY2dRRXlueFp6aVNsQVFGdjNDOWRUT21CaTIwWUc5RFY5SFJHYktEWGFjU2hOMVRSb2RsbkE4WWg3Tzlway1BSl9jSEFub1A1VGdIMjV6Rw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon schedules May 7 webcast to discuss its Q1 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOWGpxaTJRbFl0UE1NTjJaMWYzcFNIUjNpcGtJXzhWMERQMy1yb2lVdDdKUjF2VmFvR0NkcVFNQ3NOTDhGOTkwdjlnZEh3VDd1RW9YWUVpSEptWWRHdFZINExTS2hRc1Jrbm1TQTNGRXdYd29RU0J5cW5sOHpldERRVGVjbjFIWk5fUUpYNVNsZFkwV0g2dlNBd0tsQWlRNEZGLXBFOExZeHIyVTE4dmxHQ2pxbVRzLW9T?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNVTVkeHdfSlRYNzd4ZmRZM1dNWHRlVFN2ekwzelJBYUJ0Z1l1c0wwYktmNXhEMkFjeUljMWdrLXBXY2dTalNBNFctb0o0Q0lBb3hVOEVxR0VzeGk2ODF3ZjdCQml4RDUyNllERi1zVUFxMjhJY3pXR1FCWkw2YTV3SmVReUN4RnZ2eHR3eTdJb1FNRThMeDRCdWd4Z2lUU1Q2RXhxb0hWYy1EaDY0NTVQRg?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting Around Pilavapadin And Valuation Assumptions", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPdy10YS0wQmhFcHg0eFJPLUF5VzFfWjg3eHM2Ykw5YVN5MVFVb05hZFV4T2loQ3I5WXl2bkt0c2F3aDR1b2lMZ0xDb3VSQi1hMV9rTWh5a1BHQ0VaWjYtX2NDTm55R0l4U1NlMnhzZFp3UFVjUjF4YzRNcW1hTFNJV0V6Ym54Sk5LOE9IMFVDcVNHSFRrMUtpbmY5WFo3WFg0WmMtMVdRTDlQS2Rv?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting With Fine Tuned Targets And Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQT2p4MFdPRTk0R1ZuSjhUclhnNDRDRjVwQUFIN0lvMmxxcnl4LWdvNTU5UnI0d1JvSUlFQ0ZSRG9uMml6d1AycUFoUlVsUVNieUNxWXgxaEZIYTFZMEVVUkpJM0tELUVEdVE3MXQ4SFdIckc0Y0lmaUw3UE5Zakxic0xOR25tVVlvc2haY3hmdGJfOGs?oc=5", "source_name": "Market source", "published_at": "2026-02-22T08:00:00+00:00", "published_display": "22 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Completes Public Offering of Common Stock and Concurrent Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQVUR6OEJhcHBiNThTM2xRaGhzSGhMUUV1elhxbktqbUhWS0NSRE1PS1RnOXRCT19scF9Fdy1OcS05YzdqWlRMS0VmVTN3eXV2akVoeGdhY3ZUVWpEUGhxR09HQ212T3U5Uk9YTVFVMTdMVnV0Y3duN1NfWDdQMllUM3lsU0pxYTU2Tm1HYlBYQUJ3dnhURTJpeUdIT1JHcFF0RzRFcWxHS19LenluSGhMYmZHcGdXQWE4R1ZQUlkydmktMGFqcXpzZWw3aw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Announces Pricing of $41.6 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOX296Y0tRbnNzNFk0ZW1WX09QRzBkNWpVWjlJRjBORUMyOXc2LXRPNlJJZ29PN0MtNTM3U0RNenF0aXZFc21LZV9NRVpnNWdKT2QwMEJ0WEQ2dDcyMTF0c2s2dUp4emM5Sm8xUDFsbDF4bFpJbWdrNjRUQ05OSWw0ZklOMUpYMDJxTVF2dkljTE1kc0ozQXVnd0JCMXRnbUhPemZ0ZUR5VWhwejFJWnZFR0NTc1hKaU5tQjRTTGl4OGxRVVU?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals prices public offering at $1.30 per share", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPODJSdHg3QVFtOWJGRmFJS1I4cWNBTHdGcG5ZWE9mdWVTeVpZY2FqUWhWbUFjLU1BZE9Ib3JEeWtCWUxVc2cwZkRGUU13SXhSZFZvaE5SbFZnaGVXOHlpTDlrY3I5bDZQaUFQa2lnblZ5c3JueXJJT1BpQWdXWnItbVRwNHF3ZHRfSzcxUFltMnE0MDRIZGlPclhIWU9uRHRzSUN6b01WV0tXTjdWOWplWXQ3TnZ0LTdNWWttVA?oc=5", "source_name": "Investing.com", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Rings the Nasdaq Stock Market Closing Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNZ21GalRrNnVFY2E0SkdkYlhTSFY0T1oyWnBwWnZ1OGJoYms2Y1NOSDAxMFhqRTdSb2VGYmtTcHZTNkR1YW53dkJNeVVkUTM3SzF4R0V0NjI2alRTdENCbFJfT3luZHNHRXgxcGg2WDVLeWJCSHA5TjdsNW9kOU5BUlhMNTVGSUZxdGVSNENjeE9qTXNvUFNN?oc=5", "source_name": "Nasdaq", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "What Lexicon Pharmaceuticals (LXRX)'s Broad Russell Index Inclusion Means For Shareholders", "summary": "Lexicon Pharmaceuticals (LXRX) was recently included in several Russell indexes, including the Russell 2000 and 3000, which could boost its trading liquidity and attract new investors. However, this inclusion doesn't change the company's fundamental investment narrative, which st", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals/news/what-lexicon-pharmaceuticals-lxrxs-broad-russell-index-inclu", "source_name": "Simply Wall Street", "published_at": "2026-07-10T08:40:11", "published_display": "10 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) Short Interest & Short Float | Updated Jul 2026 $LXRX", "summary": "Lexicon Pharmaceuticals (LXRX) experienced a 21.08% increase in short interest as of June 30, 2026, reaching 30.78 million shares, representing 8.06% of the public float. The short interest ratio or \"days to cover\" stands at 4.4 days, indicating the time it would take to cover al", "url": "https://www.marketbeat.com/stocks/NASDAQ/LXRX/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-10T07:11:09", "published_display": "10 Jul 2026 07:11", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals highlights diabetes drug focus. Strategy matters more than near-term headlin", "summary": "Lexicon Pharmaceuticals (LXRX) is maintaining its focus on diabetes and metabolic disease therapies, emphasizing its pipeline strategy within the competitive US biopharma market. The company develops targeted therapies for defined patient populations, concentrating on cardiometab", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/lexicon-pharmaceuticals-highlights-diabetes-drug-focus-strategy-matters/69717350", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T21:51:00", "published_display": "07 Jul 2026 21:51", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Lexicon Pharmaceuticals Inc (LXRX)", "summary": "This article examines the historical performance of investing $1,000 in Lexicon Pharmaceuticals Inc (LXRX) over one, five, and ten years, comparing its returns to the S&P 500. It also provides an in-depth profile of Lexicon Pharmaceuticals, detailing its biopharmaceutical product", "url": "https://www.stocktitan.net/tools/stock-return-calculator/LXRX", "source_name": "Stock Titan", "published_at": "2026-07-04T04:09:42", "published_display": "04 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) Gains on Russell 3000 Inclusion", "summary": "Lexicon Pharmaceuticals (LXRX) has seen more than a 15% gain over the past month, largely due to its inclusion in the Russell 3000 index and strong Q1 2026 earnings, which surpassed expectations significantly. The company reported $21.1 million in revenue, a 1,523% year-over-year", "url": "https://www.insidermonkey.com/blog/lexicon-pharmaceuticals-lxrx-gains-on-russell-3000-inclusion-1794180/", "source_name": "Insider Monkey", "published_at": "2026-07-03T13:39:35", "published_display": "03 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Lexicon Pharma\u2019s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX)", "summary": "Lexicon Pharmaceuticals, Inc. was added to various Russell indexes on June 27, 2026, increasing its visibility to institutional investors. While this expanded index inclusion is significant for potential trading volume and ownership, the company's core investment narrative still ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals/news/how-lexicon-pharmas-expanded-russell-index-footprint-shapes", "source_name": "Simply Wall Street", "published_at": "2026-07-02T04:09:42", "published_display": "02 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) Joins Russell Indexes, Is The Stock Still A Bargain?", "summary": "Lexicon Pharmaceuticals (LXRX) has been added to multiple Russell indexes, which is expected to increase its visibility among investors after a period of strong share price growth. Despite a \"most popular narrative\" suggesting the stock is 30% undervalued at $3.77 due to its prom", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals/news/lexicon-pharmaceuticals-lxrx-joins-russell-indexes-is-the-st", "source_name": "Simply Wall Street", "published_at": "2026-06-30T05:10:26", "published_display": "30 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2500 Growth Benchmark", "summary": "Lexicon Pharmaceuticals, Inc. (NasdaqCM:LXRX) has been added to the Russell 2500 Growth Benchmark. The biopharmaceutical company is actively involved in the research and development of drug candidates and the commercialization of INPEFA (sotagliflozin) for heart failure and type ", "url": "https://www.marketscreener.com/news/lexicon-pharmaceuticals-inc-nasdaqcm-lxrx-added-to-russell-2500-growth-benchmark-ce7f5fdfdb8bf32c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:26:00", "published_display": "29 Jun 2026 16:26", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Growth Benchmark", "summary": "Lexicon Pharmaceuticals, Inc. (NasdaqCM:LXRX) has been added to the Russell 2000 Growth Benchmark. The biopharmaceutical company focuses on researching and developing drug candidates and commercializing INPEFA (sotagliflozin), which reduces cardiovascular risks. Lexicon is also d", "url": "https://www.marketscreener.com/news/lexicon-pharmaceuticals-inc-nasdaqcm-lxrx-added-to-russell-2000-growth-benchmark-ce7f5fdedc8ff326", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:12:54", "published_display": "29 Jun 2026 15:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 3000E Growth Benchmark", "summary": "Lexicon Pharmaceuticals, Inc. (NasdaqCM:LXRX) has been added to the Russell 3000E Growth Benchmark. The biopharmaceutical company focuses on researching, developing, and commercializing drug candidates, including INPEFA (sotagliflozin) for cardiovascular and kidney conditions, pi", "url": "https://www.marketscreener.com/news/lexicon-pharmaceuticals-inc-nasdaqcm-lxrx-added-to-russell-3000e-growth-benchmark-ce7f5fdedb81f625", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T03:44:06", "published_display": "29 Jun 2026 03:44", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LXRX Surges As Traders Pounce On Strong Breakout", "summary": "Lexicon Pharmaceuticals Inc. (LXRX) stock has surged by 11.76% due to bullish sentiment driven by promising drug development progress. The stock has broken out from low $2s to above $2.55, indicating strong buying pressure despite the company's significant operating losses. Analy", "url": "https://stockstotrade.com/news/lexiconpharmaceuticalsinc-lxrx-news-2026_06_28/", "source_name": "StocksToTrade", "published_at": "2026-06-28T15:37:00", "published_display": "28 Jun 2026 15:37", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LXRX Stock Climbs As Bullish Momentum Attracts Short-Term Traders", "summary": "Lexicon Pharmaceuticals Inc. (LXRX) stock has climbed by 11.76% due to positive drug development news and bullish investor sentiment. Despite rapid revenue growth, the company faces deep losses, but strong liquidity provides a runway for operations. Technical analysis indicates a", "url": "https://stockstotrade.com/news/lexiconpharmaceuticalsinc-lxrx-news-2026_06_27/", "source_name": "StocksToTrade", "published_at": "2026-06-27T15:10:31", "published_display": "27 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LXRX Climbs As Bulls Press Multi-Day Breakout", "summary": "Lexicon Pharmaceuticals Inc. (LXRX) is experiencing a multi-day breakout driven by positive drug development news, with its stock climbing significantly. Despite strong revenue growth, the company faces deep losses, but its strong balance sheet and high liquidity provide a runway", "url": "https://www.timothysykes.com/news/lexiconpharmaceuticalsinc-lxrx-news-2026_06_27/", "source_name": "Timothy Sykes", "published_at": "2026-06-27T14:10:31", "published_display": "27 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals stock hits 52-week high at $2.53 By Investing.com", "summary": "Lexicon Pharmaceuticals (LXRX) stock reached a 52-week high of $2.53, showing significant momentum with increases of approximately 14% over the past week, 86% over six months, and 99% year-to-date, reflecting a 206.37% increase over the last year. Despite this surge and a strong ", "url": "https://ng.investing.com/news/stock-market-news/lexicon-pharmaceuticals-stock-hits-52week-high-at-253-93CH-2576373", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T14:10:26", "published_display": "27 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals stock hits 52-week high at $2.53", "summary": "Lexicon Pharmaceuticals (LXRX) stock reached a 52-week high of $2.53, showing strong momentum with significant gains over the past week, six months, and year-to-date. This performance, coupled with revenues surging to $21.1 million in Q1 2026, reflects investor confidence, though", "url": "https://www.investing.com/news/company-news/lexicon-pharmaceuticals-stock-hits-52week-high-at-253-93CH-4763333", "source_name": "Investing.com", "published_at": "2026-06-27T13:39:27", "published_display": "27 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:LXRX)", "summary": "This article provides an overview of Lexicon Pharmaceuticals, Inc. (LXRX) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financials, such as recent revenue and net income, market capitalization, and upcoming earnin", "url": "https://www.tradingview.com/symbols/NASDAQ-LXRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T00:38:50", "published_display": "26 Jun 2026 00:38", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why You Should Add LXRX Stock to Your Portfolio Now", "summary": "Lexicon Pharmaceuticals (LXRX) is highlighted as an investment opportunity due to its advancing cardiometabolic franchise, primarily driven by its drug sotagliflozin (Inpefa). The company is pursuing label expansion for sotagliflozin into hypertrophic cardiomyopathy and type 1 di", "url": "https://www.tradingview.com/news/zacks:046657109094b:0-here-s-why-you-should-add-lxrx-stock-to-your-portfolio-now/", "source_name": "TradingView", "published_at": "2026-06-22T14:40:38", "published_display": "22 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 87, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Stock - Sunday background on strategy and trials", "summary": "This article provides background on Lexicon Pharmaceuticals (LXRX), a biotech company focusing on cardiovascular and metabolic diseases. It highlights the company's approved heart failure drug Inpefa, its clinical development strategy, and financial considerations. While there wa", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/lexicon-pharmaceuticals-stock-sunday-background-on-strategy-and-trials/69598354", "source_name": "AD HOC NEWS", "published_at": "2026-06-21T18:10:52", "published_display": "21 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Inc (LXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Lexicon Pharmaceuticals Inc (LXRX) has an earnings forecast score of 7.60, ranking 281st in the Biotechnology & Medical Research industry. Analysts project an average price target of $1.90 with a \"Buy\" rating based on 5 analysts. The company's recent EPS was -$0.04, with the next", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lxrx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T06:41:23", "published_display": "18 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Inc (LXRX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Lexicon Pharmaceuticals Inc (LXRX) currently holds a financial score of 8.90, ranking 23rd in the Biotechnology & Medical Research industry, indicating stable financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 157", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lxrx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T05:41:23", "published_display": "18 Jun 2026 05:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Inc (LXRX) Institutional Confidence", "summary": "Lexicon Pharmaceuticals Inc (LXRX) has an institutional shareholding score of 5.00, placing it 133rd out of 388 in its industry. The institutional shareholding proportion is 67.79%, a slight decrease from the previous quarter. Steven Cohen is the largest institutional shareholder", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lxrx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T02:41:23", "published_display": "18 Jun 2026 02:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Peripheral Neuropathic Pain Market Positioned for Significant Commercial Growth by 2034 \u2013 DelveInsight | Gr\u00fcnenthal and Averitas Pharma, Scilex Pharma, Apurano Pharma, Lexicon Pharma, Helixmith", "summary": "The Peripheral Neuropathic Pain market is projected for significant growth by 2034, driven by increasing disease prevalence, awareness, and the launch of multiple pipeline products. In 2023, the global market was valued at approximately USD 12,000 million, with the US showing the", "url": "https://www.barchart.com/story/news/2482391/peripheral-neuropathic-pain-market-positioned-for-significant-commercial-growth-by-2034-delveinsight-grnenthal-and-averitas-pharma-scilex-pharma-apurano-pharma-lexicon-pharma-helixmith", "source_name": "Barchart.com", "published_at": "2026-06-16T22:09:10", "published_display": "16 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals vs Pfizer: Comparing a Small Biotech with a Global Drugmaker - News and Statistics", "summary": "This article compares Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE), highlighting the contrast between a small, growing biotech firm and a large, established pharmaceutical giant. It delves into their recent financial performances, noting Lexicon's significant revenue growth bu", "url": "https://www.indexbox.io/blog/lexicon-pharmaceuticals-vs-pfizer-biotech-growth-vs-pharma-scale-in-2026/", "source_name": "IndexBox", "published_at": "2026-06-11T15:10:18", "published_display": "11 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/ede98e74-9fd6-3733-b068-fb42fba270a9/lexicon-pharmaceuticals-vs..html", "source_name": "Motley Fool", "published_at": "2026-06-11T14:05:55+00:00", "published_display": "11 Jun 2026 14:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQRlBLNVlPOWk3bEstSU5CMFRMUGtiYU9NUkluMThVZHNJUUF4dnRIZnNZckczenpVTnhMdVFXbFJURE0zVExpZm5zTnl4WEpyWUh1WVREVUxDekdRZ2UtenFiY2tSSC1DUGozRTVqVnU5Ry1lS3pabHBJbFMxdWhON09RYUdsNHJHTDdpa3VqTE01eDNkS1R3MkRLVUlKZko0RXZSdA?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) director exercises 89,312 RSUs into shares", "summary": "Lexicon Pharmaceuticals director Ivan Cheung converted 89,312 restricted stock units (RSUs) into common shares on June 3, 2026, at a price of $0.00 per share. Following this non-cash equity award event, Cheung directly holds 89,312 common shares, with no remaining restricted stoc", "url": "https://www.stocktitan.net/sec-filings/LXRX/form-4-lexicon-pharmaceuticals-inc-insider-trading-activity-c08ebc12c05f.html", "source_name": "Stock Titan", "published_at": "2026-06-05T17:39:57", "published_display": "05 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into 213,771-share stake", "summary": "Lexicon Pharmaceuticals director Sam L. Barker converted 89,312 restricted stock units (RSUs) into common shares on June 3, 2026, receiving 89,312 shares at $0.00 per share. This transaction was an equity compensation event, not an open-market trade. Following the conversion, Bar", "url": "https://www.stocktitan.net/sec-filings/LXRX/form-4-lexicon-pharmaceuticals-inc-insider-trading-activity-87d03f6ffef5.html", "source_name": "Stock Titan", "published_at": "2026-06-05T04:08:54", "published_display": "05 Jun 2026 04:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] LEXICON PHARMACEUTICALS, INC. Insider Trading Activity", "summary": "LEXICON PHARMACEUTICALS, INC. director Christopher J. Sobecki exercised 89,312 restricted stock units, converting them into an equivalent number of common shares. Following this transaction, his direct holdings in the company amount to 293,177 shares of common stock. The transact", "url": "https://www.stocktitan.net/sec-filings/LXRX/form-4-lexicon-pharmaceuticals-inc-insider-trading-activity-486e19991df5.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:39:14", "published_display": "04 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQal9jcWdHa0ZtcVJlcmNuSnRkSThHck44UGJuU0hkQU1jOEZpejJXeExiOEk1dGhXUlJNVE12R2hpbDlRUVgtYkx6cDBGVzdmRDJPenJEeE05VlkyUVZLSEV2RUM1c284Y0NnUldVdGY2Sjg3WF96eEZXY1lOSUUtS3N2M0JwVktva2RQM2tSNm1BR0x6NHkyUGpPZm1UaXg3aTlYVDdkaE9NbkJhdWNLNFEyaDg?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into common stock holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOMW82d1p5eFlCSlZuTWdDTi03dU0xTGJIMTFaeGpyR0ZwRktOQ0tnTHJQSnl5RzlVaUVrSlVoWU5nQldCS2RFbDZIRnlQRkNJdnZIRldDMWNPVmQtRjhUYlVFb0xlTlZ2V3dOR1Q0V2tSTkZMRUtSNDhidUpDWmVKaG1GRTRTby12NkZxTFhtbWlweXdwZElaMDhxcmpYN1UweHdDS29RNUdLclpGNHQ1MEQxMS1rRXNDb1IwdG5n?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexicon-present-data-american-diabetes-120000318.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T12:00:00+00:00", "published_display": "03 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Type 1 diabetes drug data from Lexicon at ADA 2026 meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSi1aeXJUS1RrTVp2Zi1mRGFfZUpLWnJYeU5STmpKdEtVMklnSWtXUVBlT1pIOXk1X0pqSEhDemxGdkh1akJwLVBFb1hfT2JnMHBIci14eTI2NlYwaEwzVWVlZkpHem1NaE41eDRLdW5GeDlxdTN5R3FsLU80WktwdGkxSjAyUHpMUkQ1TVFHNGNraW9GNEVkU24zdkNERk1LRDAxc2hWOHNVVTlidGhGX2FTZmltSWlUcW9N?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon (LXRX) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/4e91607c-2f3b-3678-ad4a-0f55b2b9dee4/lexicon-%28lxrx%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-06-01T20:40:21+00:00", "published_display": "01 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexicon-pharmaceuticals-present-2026-jefferies-123000623.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:30:00+00:00", "published_display": "28 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharma schedules Jefferies healthcare fireside chat for June 4", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPdFdzSE1pWURwQTJWNVNOSGpJYl9PQVRSLTROeFNhdkQwSTNDV2d2c2cwcXlubnBZSnJvajNnb3VzZjVYc3hQeVY1czg3Y0Roc0RpTGlqd2JkeWpaX3U1aDloOGgySEVqS3pFZjI1N2NOM0xYNm0wc3RYTXZWRWlCdFpEU3NBYmx4cEtHT1J1cG5NRVVKRjM0UDhyazBHMDBYX2NlbC1DaXpzVi1ZQ3NjR0puQXA0Y1RwVFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPX2FTbGpINHRlbE1SUlZDQ1BPa001QUhkT0FmMjNJbzU1aXdveHhrLTZPRHVibHVyTkdQenRTREt2dXFyRVZIVEROX2dfUUE3STJUdXNXWWNWR0VGUERsZno2T3pEMklYOFhmdnR0blZxbjFVa19LZk0xRUJCZ0F3bFdOSzNIMmR3ZHMyMzR0dnVmV01TYTM3NVhFVjNwQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lexicon-pharmaceuticals-present-4th-annual-123000389.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T12:30:00+00:00", "published_display": "12 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply \u2013 What's Changed", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOajkxdGU5RVBiMzcwUWF4bGR2dzB6dFd3MnBwanE3WmxXeGRpM0cyZHhoM2lsUHplNTV1UmgwMmZmRFo4Ty1WSVlrRUZoSnFDbFlpZGlMSmtqTGY2dXBWbXdDU01kS0hobGk0YWJqbFVIT3hJTjJHeDlBYWY4TVk3clZyV0lWdw?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fireside chat at Nasdaq HQ: Lexicon joins H.C. Wainwright investor event May 19", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPblA4QUtzaWljZzlTSUU1Zk03b3JDVGlnVFBZeEVzS01zaDBPZDRORjRhbk0xUXAwSnNfQlRhbVJLNXN1VzFBRnFsYzA3eWFDRG5WN0gwU1BTaU9BTGd4Z0NQQjFXY3NtZTRRam56MEdPSC1FUXNTNGxuWkJmb2JENFcxZnVqZWVLeUdOUllZZW1VYWNHUXJ1QVlxeVdXbUttdlJpRkF2U2xMY05RRnZtWDVySlpjVzJjVjVaZ093SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQX2RiMV84RU14NklhcjdIMTVJSzNmQmNDcWRpeF95V0QybUtacUZEVkNKQllNZF9ab1p0aFJnYktXcG1TckJnaXFYY3oyQnhZRGpfcy1DdFY0TGZzV0JnZFR6bVppVXcwMzNneDFNalROdi14U2NRa3JPbTJ4eDJGbEo5VHlVWGo4bEFNZ0w0NTdqQVB1TzlMOUFGQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNX0VNbGthY2RJNnB5aTNEQ293UlN3SEthd01wMWhhdC1wRWFqaF9JNGJVUnZuTWZ1eTJ3V3l1LTFubGZ2NEtjWEg3MDBiRXJYRWhpLTVONTR0T2xReUFJY2dVNHRCTk4yaXNsOGRUQVhJeUdhQlZpY040SnRacVFldWswM19NVzY1NTZRRmhNNzJhTGJlNGIyS19YMmdCZ1RUWkVWazE0ZlpBQ3JES1E?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) Quarterly Revenue Drop Reinforces Concerns Over Persistent Losses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon targets diabetes filing, heart trial, obesity study milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOMW5yMHlmYUJXRk9adF9vc3pqT3pFY0Rkckp1ZUVlNzcxWnBDbUhBQWg1LTlmdGlRUXNYUHUxa3ZSWW1saFMtaXZfSFpGTUw0SVd2UF9XR0NRWEoxN2NuNEdkckhBb3AwU2JLTDB3bEJqSk5oYWdydlJXc1dxMmRKMmxDOXQ5WjM0TUJTZzBqQXozT25Kc2V4VTVWMWRUNGNKY1VrTHVDMXB1b2ZiV05kZDY1T3RCdmpObzFvS3BzR3Y?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNN2ExOHBkajhTVFNvYU1RTDZXNVlzSWNZTFQ2REVYRVdzVDVSYkIweWhtSGRBVlB5bFM1d1dfa0tjNGRkRm8zdTlUTnFNM3BVdnV0VTcwVlE4Q1pLcTluUmYtY2dRRXlueFp6aVNsQVFGdjNDOWRUT21CaTIwWUc5RFY5SFJHYktEWGFjU2hOMVRSb2RsbkE4WWg3Tzlway1BSl9jSEFub1A1VGdIMjV6Rw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon schedules May 7 webcast to discuss its Q1 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOWGpxaTJRbFl0UE1NTjJaMWYzcFNIUjNpcGtJXzhWMERQMy1yb2lVdDdKUjF2VmFvR0NkcVFNQ3NOTDhGOTkwdjlnZEh3VDd1RW9YWUVpSEptWWRHdFZINExTS2hRc1Jrbm1TQTNGRXdYd29RU0J5cW5sOHpldERRVGVjbjFIWk5fUUpYNVNsZFkwV0g2dlNBd0tsQWlRNEZGLXBFOExZeHIyVTE4dmxHQ2pxbVRzLW9T?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNVTVkeHdfSlRYNzd4ZmRZM1dNWHRlVFN2ekwzelJBYUJ0Z1l1c0wwYktmNXhEMkFjeUljMWdrLXBXY2dTalNBNFctb0o0Q0lBb3hVOEVxR0VzeGk2ODF3ZjdCQml4RDUyNllERi1zVUFxMjhJY3pXR1FCWkw2YTV3SmVReUN4RnZ2eHR3eTdJb1FNRThMeDRCdWd4Z2lUU1Q2RXhxb0hWYy1EaDY0NTVQRg?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting Around Pilavapadin And Valuation Assumptions", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPdy10YS0wQmhFcHg0eFJPLUF5VzFfWjg3eHM2Ykw5YVN5MVFVb05hZFV4T2loQ3I5WXl2bkt0c2F3aDR1b2lMZ0xDb3VSQi1hMV9rTWh5a1BHQ0VaWjYtX2NDTm55R0l4U1NlMnhzZFp3UFVjUjF4YzRNcW1hTFNJV0V6Ym54Sk5LOE9IMFVDcVNHSFRrMUtpbmY5WFo3WFg0WmMtMVdRTDlQS2Rv?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting With Fine Tuned Targets And Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQT2p4MFdPRTk0R1ZuSjhUclhnNDRDRjVwQUFIN0lvMmxxcnl4LWdvNTU5UnI0d1JvSUlFQ0ZSRG9uMml6d1AycUFoUlVsUVNieUNxWXgxaEZIYTFZMEVVUkpJM0tELUVEdVE3MXQ4SFdIckc0Y0lmaUw3UE5Zakxic0xOR25tVVlvc2haY3hmdGJfOGs?oc=5", "source_name": "Market source", "published_at": "2026-02-22T08:00:00+00:00", "published_display": "22 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Completes Public Offering of Common Stock and Concurrent Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQVUR6OEJhcHBiNThTM2xRaGhzSGhMUUV1elhxbktqbUhWS0NSRE1PS1RnOXRCT19scF9Fdy1OcS05YzdqWlRMS0VmVTN3eXV2akVoeGdhY3ZUVWpEUGhxR09HQ212T3U5Uk9YTVFVMTdMVnV0Y3duN1NfWDdQMllUM3lsU0pxYTU2Tm1HYlBYQUJ3dnhURTJpeUdIT1JHcFF0RzRFcWxHS19LenluSGhMYmZHcGdXQWE4R1ZQUlkydmktMGFqcXpzZWw3aw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Announces Pricing of $41.6 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOX296Y0tRbnNzNFk0ZW1WX09QRzBkNWpVWjlJRjBORUMyOXc2LXRPNlJJZ29PN0MtNTM3U0RNenF0aXZFc21LZV9NRVpnNWdKT2QwMEJ0WEQ2dDcyMTF0c2s2dUp4emM5Sm8xUDFsbDF4bFpJbWdrNjRUQ05OSWw0ZklOMUpYMDJxTVF2dkljTE1kc0ozQXVnd0JCMXRnbUhPemZ0ZUR5VWhwejFJWnZFR0NTc1hKaU5tQjRTTGl4OGxRVVU?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals prices public offering at $1.30 per share", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPODJSdHg3QVFtOWJGRmFJS1I4cWNBTHdGcG5ZWE9mdWVTeVpZY2FqUWhWbUFjLU1BZE9Ib3JEeWtCWUxVc2cwZkRGUU13SXhSZFZvaE5SbFZnaGVXOHlpTDlrY3I5bDZQaUFQa2lnblZ5c3JueXJJT1BpQWdXWnItbVRwNHF3ZHRfSzcxUFltMnE0MDRIZGlPclhIWU9uRHRzSUN6b01WV0tXTjdWOWplWXQ3TnZ0LTdNWWttVA?oc=5", "source_name": "Investing.com", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lexicon Pharmaceuticals Rings the Nasdaq Stock Market Closing Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNZ21GalRrNnVFY2E0SkdkYlhTSFY0T1oyWnBwWnZ1OGJoYms2Y1NOSDAxMFhqRTdSb2VGYmtTcHZTNkR1YW53dkJNeVVkUTM3SzF4R0V0NjI2alRTdENCbFJfT3luZHNHRXgxcGg2WDVLeWJCSHA5TjdsNW9kOU5BUlhMNTVGSUZxdGVSNENjeE9qTXNvUFNN?oc=5", "source_name": "Nasdaq", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 64, "sentiment_summary": {"positive": 26, "negative": 3, "neutral": 35, "score": 59, "total": 64, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 18.7, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 11.55, "count": 23}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 26, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 2.22, "latest_week": "2026-07-10", "one_week_move": -4.3, "four_week_move": 15.6, "twelve_week_move": 18.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.093446, "market_dynamics_buy_signal": false, "relative_strength": 26.609056, "fair_value_gap": 56.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 45.801, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.3% over one week, +15.6% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 16}, {"label": "Stock Titan", "count": 10}, {"label": "Simply Wall Street", "count": 3}, {"label": "www.marketscreener.com", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "AD HOC NEWS", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 23}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-4.3% over one week, +15.6% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "What Lexicon Pharmaceuticals (LXRX)'s Broad Russell Index Inclusion Means For Shareholders"}], "updated_at": "2026-07-18T08:46:52.279733+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}